论文信息 - Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

[1] R. Sarode,et al. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report , 2014, Transfusion.

[2] G. Nogales-Gadea,et al. Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis Patients , 2014, The Journal of Immunology.

[3] J. Raval,et al. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura , 2014, British journal of haematology.

[4] C. Neunert. Current management of immune thrombocytopenia. , 2013, Hematology. American Society of Hematology. Education Program.

[5] S. Opat,et al. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. , 2013, The New England journal of medicine.

[6] D. C. Henckel,et al. Case report. , 1995, Journal.